FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

Merck news from FierceBiotech

News

Merck turns to Ranbaxy for $100M R&D effort

India's Ranbaxy has flexed its research muscles once again, this time signing a five-year pact with Merck to develop new anti-infectives. Ranbaxy, which received an undisclosed upfront payment, says Read more...

Traditional remedies offer opportunities, challenges

The Financial Times delves into the push to develop new therapeutics from traditional Chinese and Indian remedies. There have been successes, including the anti-malarial artemether, which was Read more...

Analyst predicts a long delay for Merck's Cordaptive

There's more bad news--or analysis--for Merck's drug development efforts. After the FDA Read more...

Merck wins the 'silver' for worst news week

WBB Securities analyst Steve Brozak has issued a symbolic "silver medal" to Merck for worst news week. In a triple whammy rarely accomplished in the drug world, Merck had two experimental Read more...
Tags: Vioxx   Merck   pipeline  

Merck shares hammered after FDA rejects Cordaptive

Shares of Merck were sliding again this morning on the news that the FDA has turned thumbs down on MK-0524A, its new cholesterol therapy. The stock dropped eight percent after regulators announced Read more...

Avastin, Erbitux battle for lung cancer market

Genentech's stock was down this morning on results from a Phase III study of Avastin for non-small cell lung cancer. While the drug did meet the primary endpoint--an improvement in progression-free Read more...

Dynavax shares hammered on FDA clinical hold

Dynavax's shares took a beating this morning after the FDA placed a clinical hold on the company's trial of Heplisav, a hepatitis B therapy. According to the Motley Fool, "[t]he agency put the Read more...
Tags: Dynavax   Merck   Heplisav   hepatitis B   Phase III   Phase II   FDA  

Codexis blueprints $100 million IPO

Codexis has decided to wade into frigid market waters with an IPO that may be used to raise upwards of $100 million. The company makes biocatalysts: enzymes or microbes that cause chemical Read more...
Tags: Merck   Pfizer   Bristol-Myers Squibb   IPO   Codexis   ipos  

ALSO NOTED: Crucell shares up on TB data; Celera, Merck ink cancer deal; and much more...

> A federal patent office may appeal a court ruling that threw out a new cap limiting the number of times a company can resubmit patent applications. That change was aggressively contested by the Read more...

Press Releases

Celera Genomics Group-an Applera Corp. Business Grants License to Merck for Cancer Targets

Celera Genomics Group-an Applera Corp. Business Grants License to Merck for Cancer Targets /10/2008 ALAMEDA, Calif. -- Celera, an Applera Corporation business, today announced a two year exclusive Read more...

Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests

Experimental Weight-loss Drug Cuts Appetite, Burns More Energy, Study Suggests The first clinical studies of an experimental drug have revealed that obese people who take it for 12 weeks lose Read more...

Merck Sells Pennsylvania Chemicals Plant

Merck Sells Pennsylvania Chemicals Plant PHILADELPHIA, Jan. 1 -- PRWT Services, Inc., a minority-owned business enterprise, today announced that it has, through its wholly-owned subsidiary, Cherokee Read more...

PRESS RELEASE: Idera Pharmaceuticals, and Merck Forge $400 Million Cancer Drug Deal

Idera Pharmaceuticals, and Merck Forge $400 Million Cancer Drug Deal CAMBRIDGE, Mass. -- Idera Pharmaceuticals announced today that it has entered into a worldwide licensing and collaboration Read more...

PRESS RELEASE: Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB and COMVAX

Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB and COMVAX WHITEHOUSE STATION, N.J., Dec. 12, 2007 - Merck & Co., Inc. announced today that the Company has initiated a voluntary Read more...